Dishman Carbogen Amcis

Dishman Carbogen Amcis is an India-based multinational pharmaceutical services and manufacturing group serving pharmaceutical and biopharmaceutical companies. Its activities combine the production of marketable molecules with contract research, process development, clinical-supply support, and commercial manufacturing. The company is particularly associated with active pharmaceutical ingredients (APIs), pharmaceutical intermediates, highly potent and cytotoxic compounds, quaternary ammonium compounds, specialty chemicals, vitamin D products, cholesterol and lanolin derivatives, and sterile parenteral medicines. The business originated in 1983 when Janmejay R. Vyas founded the Dishman Group. In its early years, the group concentrated on research and development for in-house manufacturing technologies, especially quaternary ammonium compounds and APIs. Its first manufacturing facility was established at Naroda in Ahmedabad in 1987. The group later expanded to Bavla, also in the Ahmedabad region, beginning in 1996; Bavla became its principal headquarters and one of its central Indian manufacturing locations. Dishman developed an international operating model through acquisitions and the integration of specialized pharmaceutical businesses. The group acquired CARBOGEN AMCIS in stages, including the Swiss business in 2006, the United Kingdom operation in 2005, the Netherlands vitamin-related facility from Solvay in 2007, and the French Riom operation in 2012. A facility in Vionnaz, Switzerland, was added by CARBOGEN AMCIS in 2014. These transactions broadened the group's capabilities beyond Indian bulk-chemical production into European pharmaceutical development, highly potent drug manufacturing, sterile parenteral products, and clinical-trial supply. The group operates through four broad business units. Dishman Specialty Chemicals manufactures phase-transfer catalysts, intermediates, fine chemicals, and related materials for pharmaceutical, cosmetic, and other industrial applications. Dishman Vitamins and Chemicals focuses on vitamin D2, vitamin D3, vitamin D analogues, cholesterol, and lanolin-related products. Dishman Disinfectants produces antiseptic and disinfectant formulations. Dishman Custom Services combines Dishman's contract research activities with CARBOGEN AMCIS and supports process research and development, API supply for clinical trials, and commercial API manufacturing, including cytotoxic and cytostatic medicines. Its site network spans India, Europe, and China. Indian facilities at Naroda and Bavla manufacture phase-transfer catalysts, pharmaceutical intermediates, APIs, and fine chemicals. The Shanghai operation produces intermediates and APIs, including highly potent products. European sites provide a more specialized range of services: Veenendaal in the Netherlands produces vitamin and steroid-related products; Swiss facilities at Bubendorf, Aarau, Hunzenschwil, and Vionnaz support API development, complex intermediates, highly potent drugs, and antibody-drug-conjugate warheads and linkers; Riom in France focuses on sterile parenteral products; and Manchester in the United Kingdom supports non-GMP production of complex pharmaceutical intermediates. Dishman Carbogen Amcis therefore occupies a business-to-business position rather than a consumer-facing pharmaceutical-brand position. Its value proposition rests on integrated chemistry, multi-site manufacturing, regulatory and development support, and the ability to handle complex, potent, or technically demanding pharmaceutical materials from research and clinical development through commercial supply. The company is listed in India and has an international workforce and customer base, although detailed current financial, leadership, and operational information is not established in the supplied reference material.

The Dishman Group was established in 1983 by Janmejay R. Vyas. From its outset, the group pursued research and development of proprietary manufacturing technologies for quaternary ammonium compounds and active pharmaceutical ingredients. This technical orientation shaped the company's later role as both a producer of marketable molecules and a contract manufacturing and development organization. Dishman's first manufacturing facility was built at Naroda in Ahmedabad in 1987. The group subsequently expanded in the Ahmedabad area, beginning development at Bavla in 1996. Bavla became the group's principal headquarters, while the Naroda and Bavla sites developed capabilities in phase-transfer catalysts, pharmaceutical intermediates, APIs, and fine chemicals. The company expanded internationally through acquisitions and the creation of a multi-country manufacturing network. Dishman acquired the United Kingdom operation of CARBOGEN AMCIS in 2005 and acquired the Swiss CARBOGEN AMCIS business in 2006. The Swiss sites at Bubendorf, Aarau, and Hunzenschwil brought expertise in API development, complex intermediates, highly potent compounds, and production for clinical and commercial use. In 2007, the group acquired a vitamin-related facility in Veenendaal, the Netherlands, from Solvay, adding production of vitamin D products, cholesterol, and lanolin-related materials. The international network expanded further in France. CARBOGEN AMCIS acquired the Riom operation in 2012. The site specializes in developing and producing sterile parenteral products for clinical trials. In 2014, CARBOGEN AMCIS acquired a facility in Vionnaz, Switzerland, designed for highly potent API work, including the production of potent warheads and linkers used in antibody-drug-conjugate programs. By integrating these businesses, Dishman developed a broad pharmaceutical-services platform spanning research, process development, clinical supply, and commercial manufacture. Its Indian operations remained important for specialty chemicals, intermediates, APIs, and disinfectant-related activities, while the CARBOGEN AMCIS sites contributed specialized European capabilities in complex and potent pharmaceutical materials, sterile dosage forms, and development-stage manufacturing. A Shanghai operation added manufacturing capacity for intermediates and APIs, including highly potent drugs. The group is organized around four principal business areas: Dishman Specialty Chemicals; Dishman Vitamins and Chemicals; Dishman Disinfectants; and Dishman Custom Services. The last of these incorporates contract research and CARBOGEN AMCIS activities, covering process research and development, clinical-trial API supply, and commercial API production. The resulting organization serves pharmaceutical and biopharmaceutical customers rather than selling primarily to consumers. Dishman Carbogen Amcis is listed on India's Bombay Stock Exchange and National Stock Exchange. The supplied reference material describes the company as employing more than 1,000 people worldwide and operating manufacturing or development facilities in India, China, Switzerland, France, the Netherlands, and the United Kingdom. Detailed information about later corporate developments, current executives, financial performance, and present ownership is not established in the available material.

• 2014

  Vionnaz highly potent facility added

  [1]Dishman Carbogen Amcisen.wikipedia.org

  CARBOGEN AMCIS acquired the Vionnaz, Switzerland facility, adding capabilities for highly potent APIs and antibody-drug-conjugate warheads and linkers.

• 2012

  Riom operation acquired

  [1]Dishman Carbogen Amcisen.wikipedia.org

  CARBOGEN AMCIS acquired the Riom, France site, which focuses on sterile parenteral products for clinical-trial programs.

• 2007

  Veenendaal facility acquired from Solvay

  [1]Dishman Carbogen Amcisen.wikipedia.org

  Dishman acquired the Veenendaal, Netherlands facility from Solvay, expanding into vitamin D, cholesterol, and lanolin-related products.

• 2006

  Swiss CARBOGEN AMCIS business acquired

  [1]Dishman Carbogen Amcisen.wikipedia.org

  Dishman acquired CARBOGEN AMCIS operations in Switzerland, including sites supporting API development, highly potent drugs, and complex intermediates.

• 2005

  United Kingdom CARBOGEN AMCIS operation acquired

  [1]Dishman Carbogen Amcisen.wikipedia.org

  Dishman acquired the Manchester, United Kingdom operation of CARBOGEN AMCIS, adding non-GMP production of complex pharmaceutical intermediates.

• 1987

  First manufacturing facility established at Naroda

  [1]Dishman Carbogen Amcisen.wikipedia.org

  Dishman built its first manufacturing facility at Naroda in Ahmedabad, India.

• 1983

  Dishman Group founded

  [1]Dishman Carbogen Amcisen.wikipedia.org

  Janmejay R. Vyas founded the Dishman Group, initially focusing on in-house technologies for quaternary ammonium compounds and active pharmaceutical ingredients.

A vertically integrated, business-to-business pharmaceutical development and manufacturing partner combining Indian scale in APIs and specialty chemicals with European capabilities in complex molecules, highly potent compounds, sterile parenteral products, and clinical-to-commercial supply.

• Specialty chemicals and pharmaceutical intermediates

  Dishman Specialty Chemicals

  This business manufactures phase-transfer catalysts, pharmaceutical intermediates, fine chemicals, and related materials. The products serve pharmaceutical, cosmetic, and other specialty-chemical applications, reflecting Dishman's original expertise in developing and manufacturing quaternary ammonium and related chemical compounds.

• Vitamins and steroid-related specialty chemicals

  Dishman Vitamins and Chemicals

  The unit produces vitamin D2, vitamin D3, vitamin D analogues, cholesterol, and lanolin-related products. These materials are used in pharmaceutical and cosmetic markets and are associated with the group's Veenendaal, Netherlands capabilities.

• Disinfectant and antiseptic formulations

  Dishman Disinfectants

  Dishman Disinfectants manufactures antiseptic and disinfectant formulations. The reference material identifies this as a distinct business unit, but does not specify individual product names or brand-level formulations.

• Contract research, development, and manufacturing

  Dishman Custom Services

  Dishman Custom Services provides process research and development, API supply for clinical trials, and commercial API manufacturing. Through its CARBOGEN AMCIS activities, the unit supports complex intermediates, cytotoxic and cytostatic compounds, highly potent APIs, and other technically demanding pharmaceutical programs.

• Highly potent pharmaceutical development and manufacturing

  CARBOGEN AMCIS highly potent API services

  The CARBOGEN AMCIS network provides development and manufacturing for highly potent and cytotoxic pharmaceutical materials. The Vionnaz site additionally supports potent warheads and linkers for antibody-drug-conjugate programs, while Swiss and Chinese facilities contribute related API and intermediate capabilities.

• Sterile parenteral drug development and manufacturing · 2012

  CARBOGEN AMCIS sterile parenteral services

  The Riom, France operation focuses on the development and production of sterile parenteral drugs for clinical trials. It forms part of the group's contract development and manufacturing offering for pharmaceutical and biopharmaceutical customers.

• 2014

  Addition of the Vionnaz facilityM&A

  Background

  The group was increasing its capacity for highly potent pharmaceutical materials and specialized antibody-drug-conjugate components.

  Action taken

  CARBOGEN AMCIS acquired the Vionnaz, Switzerland facility.

  Aftermath

  The facility provided capabilities for highly potent APIs, including potent warheads and linkers for antibody-drug-conjugate applications.

  Source

• 2012

  Acquisition of the Riom operationM&A

  Background

  CARBOGEN AMCIS expanded its European development and manufacturing network into sterile pharmaceutical dosage forms.

  Action taken

  CARBOGEN AMCIS acquired the Riom, France operation.

  Aftermath

  Riom added development and production of sterile parenteral drugs for clinical-trial programs.

  Source

• 2007

  Acquisition of the Veenendaal facilityM&A

  Background

  The group continued to diversify its international pharmaceutical and specialty-chemical manufacturing portfolio.

  Action taken

  Dishman acquired the Veenendaal, Netherlands facility from Solvay.

  Aftermath

  The site added manufacturing of vitamin D2, vitamin D3, vitamin D analogues, cholesterol, and lanolin-related products.

  Source

• 2006

  Acquisition of CARBOGEN AMCIS SwitzerlandM&A

  Background

  Dishman was broadening its business from Indian specialty chemicals and APIs into specialized international contract development and manufacturing.

  Action taken

  Dishman acquired the Swiss CARBOGEN AMCIS business and its sites in Bubendorf, Aarau, and Hunzenschwil.

  Aftermath

  The group gained Swiss capabilities in API development, highly potent drugs, complex intermediates, and clinical and commercial manufacturing.

  Source

• 2005

  Acquisition of the Manchester operationM&A

  Background

  Dishman sought to expand its international pharmaceutical manufacturing and development footprint through the CARBOGEN AMCIS network.

  Action taken

  Dishman acquired the CARBOGEN AMCIS operation in Manchester, United Kingdom.

  Aftermath

  The acquisition added non-GMP manufacturing of complex pharmaceutical intermediates to the group's capabilities.

  Source

1. 1Dishman Carbogen Amcisen.wikipedia.org